- Conditions
- Peripartum Cardiomyopathy, Postpartum
- Interventions
- Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo
- Drug
- Lead sponsor
- Dennis M. McNamara, MD, MS
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 56
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pediatric Hypertension
- Interventions
- NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan
- Other · Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 10 Years to 22 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heart Failure
- Interventions
- Changes of heart failure medications
- Drug
- Lead sponsor
- Alere San Diego
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 6
- States / cities
- Loma Linda, California • San Diego, California • Boston, Massachusetts + 3 more
- Conditions
- COVID-19
- Interventions
- Discontinuation of ARB/ACEI, Continuation of ARB/ACEI
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cognitive Decline, Blood Pressure, Hypertension
- Interventions
- Clinical Support Decision Tool
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Medication Adherence
- Interventions
- Increasing Medication Adherence through Physician Incentives and Messaging
- Other
- Lead sponsor
- National Bureau of Economic Research, Inc.
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Breast Cancer, Cardiotoxicity
- Interventions
- antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
- Other · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Congestive Heart Failure
- Interventions
- Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan
- Device · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease, Blood Pressure, Angiotensin-converting Enzyme Inhibitor, Angiotensin Receptor Blockers
- Interventions
- Continuation of ACEi and/or ARBs
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Stage D Heart Failure
- Interventions
- Sacubitril-Valsartan, Usual care (standard-of-care) arm
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Cardiovascular Disease
- Interventions
- oral education & written tips for remembering medications, pill box, pocket medication card, sharing information with community pharmacist, Medication use evaluations by community pharmacist, informing physician if patient has stopped a medication, Routine discharge counseling, Letter to physician/discharge summary
- Behavioral · Device · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- CTP-499, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more
- Conditions
- Type 2 Diabetes Mellitus, Hypertension
- Interventions
- Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
- Drug · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Change of treatment plan
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- ACEI or ARB, Lisinopril
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
- Interventions
- FG-3019, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 28
- States / cities
- Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo-matching dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
- Conditions
- Kidney Disease, Nephropathy, Type 2 Diabetes
- Interventions
- losartan, lisinopril
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 577
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
- Conditions
- Coronary Artery Disease
- Interventions
- High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
- Drug · Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 2,476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Hypotension, Anesthesia
- Interventions
- Methohexital, Propofol
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Myocardial Infarction, Coronary Artery Disease
- Interventions
- Full drug coverage, Usual coverage
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5,860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Type 2 Diabetes Mellitus, CKD and Albuminuria
- Interventions
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • Chula Vista, California • Concord, California + 34 more